Introducing SKINVIVE™by JUVÉDERM® for Cheek Skin Smoothness

Newport Beach Dermatology and Plastic Surgery Injectors is thrilled to announce the arrival of a groundbreaking skin treatment: SKINVIVE™ brought to market by the creators of BOTOX® and JUVÉDERM®. This revolutionary intradermal microdroplet injection is the first of its kind to be approved by the FDA for enhancing skin smoothness on the cheeks. Available starting late September 2023, at Newport Beach Dermatology and Plastic Surgery , SKINVIVE™ by JUVÉDERM® is set to redefine facial aesthetics for adults over the age of 21.


Unlike traditional dermal fillers that focus on enhancement and
augmentation, SKINVIVE™ by JUVÉDERM® was meticulously designed in collaboration with global skin health experts to address a unique need: improving cheek skin smoothness. This treatment involves injecting a smooth, hydrating hyaluronic acid (HA) gel with a touch of local anesthetic (lidocaine). SKINVIVE™ by JUVÉDERM® is a modified form of HA that helps the skin retain its natural moisture which improves skin smoothness and fine lines of cheeks. By increasing skin hydration, SKINVIVE™ by JUVÉDERM® creates a lasting glow that reflects light more effectively off the cheek area. This innovation is approved for all Fitzpatrick Skin Types I-VI, accommodating a broad range of skin tones and addressing an unmet need in the category.


Newport Beach Dermatology and Plastic Surgery Injectors participated as investigators in early clinical studies evaluating the safety and efficacy of SKINVIVE™ and is one of the first practices in the country to offer SKINVIVE™ to their patients.


It is important for patients to remember that treatments requiring dermal injection, including SKINVIVE™, Botox, and dermal fillers, if not properly administered, have the potential to result in adverse outcomes. Just because a treatment is FAD approved and deemed safe, does not mean that it is safe in all hands. Labeling a procedure as “safe” assumes it is performed by the appropriate medical professionals with substantial training and experience with facial anatomy. SKINVIVE™ by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.

SKINVIVE™ by JUVÉDERM® represents a groundbreaking advancement in dermatological care. It’s the first and exclusive intradermal microdroplet injection available in the United States, designed to enhance cheek skin smoothness. This transformative treatment delivers results that endure for up to six months when administered optimally, targeting facial skin smoothness in adults aged 21 and above.

Unlike conventional fillers, which typically augment and enhance specific areas, SKINVIVE™ by JUVÉDERM® takes a unique approach. Crafted in collaboration with renowned skin health experts, it’s a hyaluronic acid (HA) skin quality treatment that creates an entirely new category. This innovative treatment minimizes downtime while providing results that last for six months, without the need for recurring treatments.

SKINVIVE™ by JUVÉDERM® injectable gel is a smooth, hyaluronic acid (HA) gel containing a small amount of lidocaine, a local anesthetic. Unlike other facial injectables that enhance and augment, SKINVIVE™ by JUVÉDERM® focuses on increasing skin hydration to enhance cheek skin smoothness. This uniquely formulated treatment, developed in consultation with global skin health experts, leads to improved cheek skin smoothness, resulting in a sustained radiant appearance.

SKINVIVE™ by JUVÉDERM® injectable gel is specifically manufactured to enhance cheek skin smoothness, resulting in visibly more hydrated skin that lasts for six months following optimal treatment. It’s suitable for all skin types, ranging from Fitzpatrick Skin Types I to VI, catering to a broad spectrum of patients.

In alignment with FDA requirements for novel products, Allergan Aesthetics has instituted a mandatory training program for all interested providers. Successful completion of this training is a prerequisite for the purchase and administration of SKINVIVE™ by JUVÉDERM®.

SKINVIVE™ by JUVÉDERM® is administered as an injectable HA gel through a series of small injections. This treatment improves skin quality, resulting in smoother and more hydrated skin that lasts for six months following optimal treatment. To achieve the desired aesthetic outcome, an optional touch-up may be recommended one month after the initial treatment.

In the clinical study, the majority of participants reported side effects such as redness, lumps/bumps, swelling, bruising, tenderness, pain, firmness, discoloration, and itching at the injection sites, as documented in their 30-day daily diaries. These side effects were generally mild or moderate in severity, with a few experiencing severe effects. Investigators also noted needle abrasion and papules at the injection site. While rare, some participants experienced side effects lasting beyond 30 days, although most resolved within this timeframe.

SKINVIVE™ by JUVÉDERM® is best described as a skin hydrator. This innovative treatment operates beneath the skin’s surface to increase hydration, leading to improved smoothness, particularly in the cheek area.

The cost depends on how much SKINVIVE™ by JUVÉDERM® is used.

Yes. For example, botulinum toxins may be injected during your visit.

Botox® Cosmetic helps to correct the upper one-third of your face while SKINVIVE™ by JUVÉDERM® help with the lower two-thirds. This combination is widely used because it provides a considerable aesthetic improvement in only 1 to 2 weeks. If SKINVIVE™ by JUVÉDERM® is combined with a laser treatment, we usually wait a month with various lasers but sometimes can do same day procedures, depending on the modality.

To learn more about SKINVIVE™ by JUVÉDERM® please call 949.706.7886 or contact us to make an appointment with one of our cosmetic coordinators. 

Because SKINVIVE™ by JUVÉDERM® is a voluntary medical aesthetic treatment, it is not covered by insurance providers and FSA companies.

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.